PD07: Prescribing and using vitiligo treatments for limited active vitiligo: lessons from a nested process evaluation within the HI‐Light Vitiligo randomized controlled trial
Abstract
Prescribing and using vitiligo treatments for limited active vitiligo: lessons from a nested process evaluation within the HI-Light Vitiligo randomized controlled trial J. Batchelor, J. Chalmers, P. Leighton, V. Eleftheriadou, J. Ravenscroft, M. Santer, R. Haines, G. Meakin and K. Thomas University of Nottingham, Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK; and University of Southampton, Southampton, UK In the UK, people with vitiligo have mixed experiences of obtaining treatment, even with commonly used treatments such as topical corticosteroids (TCS). Narrowband ultraviolet B (NB-UVB) treatment is usually reserved for people with extensive vitiligo and given in hospital settings; the provision of home-based handheld NB-UVB is rare. The HI-Light Vitiligo Trial was a randomized controlled trial involving children (> 5 years) and adults with active vitiligo affecting < 10% of the skin. Participants were randomized to 9 months of treatment with either combination treatment with potent TCS + homebased handheld NB-UVB; TCS + dummy NB-UVB; or NB-UVB + dummy TCS. Combination treatment gave a better treatment response than potent TCS alone and was better value for money than NB-UVB or potent TCS used in isolation in the treatment of limited vitiligo. However, there are uncertainties in how best to implement this treatment combination in clinical practice. We report the findings of a process evaluation nested within the HI-Light Trial, aimed at…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.